Summary

Persistence Market Research, a prominent market research firm, has recently published an extensive report on the Bladder Cancer Treatment Drugs Market. This comprehensive analysis provides a deep dive into critical market dynamics, encompassing drivers, trends, opportunities, and challenges, offering detailed insights into the market structure.

Key Insights:

• Bladder Cancer Treatment Drugs Market Size (2024E): USD 3.8 Billion
• Projected Market Value (2033F): USD 14.8 Billion
• Global Market Growth Rate (CAGR 2024 to 2033): 16.3%

Bladder Cancer Treatment Drugs Market - Report Scope:

Bladder cancer treatment drugs are pivotal in managing and treating various stages of bladder cancer, including non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). These drugs target specific pathways and cellular mechanisms to inhibit cancer growth, improve survival rates, and enhance patient quality of life. The market caters primarily to hospitals, oncology centers, and outpatient clinics, offering a diverse array of drug types such as chemotherapy agents, immunotherapy drugs, and targeted therapies.

Market Growth Drivers:

The global bladder cancer treatment drugs market is propelled by several key factors. These include the rising global incidence of bladder cancer, advancements in drug development that target specific genetic mutations and biomarkers associated with bladder cancer, and increasing adoption of combination therapies to enhance treatment outcomes. Additionally, escalating healthcare expenditures, growing patient awareness regarding early cancer detection, and supportive governmental initiatives for cancer research contribute significantly to market expansion.

Market Restraints:

Despite optimistic growth prospects, the bladder cancer treatment drugs market encounters challenges such as the high costs linked with novel drug development, stringent regulatory requirements for drug approval, and potential adverse effects associated with chemotherapy and immunotherapy treatments. Limited reimbursement coverage for certain therapies and the necessity for personalized treatment approaches further hinder market penetration, especially in emerging economies.

Market Opportunities:

The bladder cancer treatment drugs market presents substantial growth opportunities driven by ongoing clinical trials for novel drug candidates, strategic collaborations between pharmaceutical firms and research institutions to expedite drug discovery, and advancements in precision medicine approaches for tailored cancer therapy. Additionally, the integration of biomarker-driven diagnostics and companion diagnostics enhances treatment efficacy and patient outcomes, fostering further market growth.

Key Questions Answered in the Report:

• What are the primary drivers propelling the growth of the global bladder cancer treatment drugs market?
• Which drug types and treatment modalities are driving adoption across diverse healthcare settings?
• How are technological advancements and biomarker-driven diagnostics reshaping the competitive landscape of the bladder cancer treatment drugs market?
• Who are the key players contributing to the bladder cancer treatment drugs market, and what strategies are they employing to maintain market relevance?
• What emerging trends and future prospects are anticipated in the global bladder cancer treatment drugs market?

Competitive Intelligence and Business Strategy:

Leading players in the global bladder cancer treatment drugs market, such as Pfizer Inc., Merck KGaA, and Cipla Inc., focus on innovation, clinical research, and strategic partnerships to sustain their competitive edge. These companies invest significantly in R&D to develop targeted therapies, immune checkpoint inhibitors, and combination treatments that elevate patient outcomes and extend survival rates. Collaborations with oncology centers, patient advocacy groups, and regulatory bodies facilitate streamlined drug approval processes and market access, driving advancements in bladder cancer treatment.

Key Companies Profiled:

• Pfizer Inc.
• Merck KgaA
• Merck & Co
• AstraZeneca PLC
• Roche Holding AG (Genentech)
• Astellas Pharma Inc.
• J&J (Janssen Biotech)
• Cipla Inc.
• Amneal Pharma,
• Bristol Myers Squibb Co.
• Dr Reddy’s Laboratories, Inc.
• Gilead Sciences Inc.
• Endo Pharma
• UroGen Pharma, Inc.
• Teva Pharmaceuticals (Actavis)
• Hikma Pharmaceuticals, Incyte

Market Segmentation

By Cancer Type
• Non-Muscle-Invasive Bladder Cancer
• Muscle-Invasive Bladder Cancer

By Cancer Grade
• Low-Grade Bladder Cancer
• High-Grade Bladder Cancer

By Drug Type
• Immunotherapy
• Chemotherapy
• Targeted Therapy

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Specialty Pharmacies
• Online Pharmacies

By Region
• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• The Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Market Outlook
1.2. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Key Market Trends
3.1. Key Trends Impacting the Market
4. Key Success Factors
4.1. Product Adoption Analysis
4.2. Key Strategies, by Manufacturers
4.3. Regulatory Scenario
4.4. Porters Analysis
4.5. PESTLE Analysis
4.6. Supply Chain Analysis
4.7. Funding In Research & Development
4.8. Clinical Trials Analysis
4.9. Pipeline Analysis
4.10. Disease Epidemiology, by Region
4.11. Reimbursement Scenario
4.12. Parent Market Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Pharmaceutical Industry Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Healthcare Spending
5.2.2. Increasing Prevalence of Cancer
5.2.3. Increasing Awareness and Supportive Government Initiatives
5.2.4. Increase in Funding for
5.2.5. Cancer Research
5.2.6. Increase In Product Launches
5.2.7. Strong Product Pipeline
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis - Impact Assessment
6.1.1. Impact of COVID-19 - 2024 Market Scenario
6.1.2. COVID-19 Impact Summary
7. Global Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Bladder Cancer Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis by Bladder Cancer Type, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Bladder Cancer Type, 2024-2033
8.3.1. Non-Muscle-Invasive Bladder Cancer
8.3.2. Muscle-Invasive Bladder Cancer
8.4. Market Attractiveness Analysis by Bladder Cancer Type
9. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Cancer grade
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis by Cancer grade, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Cancer grade, 2024-2033
9.3.1. Low-grade bladder cancer
9.3.2. High-grade bladder cancer
9.4. Market Attractiveness Analysis by Cancer grade
10. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Drug Type
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis by Drug Type, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast by Drug Type, 2024-2033
10.3.1. Immunotherapy
10.3.1.1. Bacillus Calmette-Guerin
10.3.1.2. Avelumab
10.3.1.3. Nivolumab
10.3.1.4. Pembrolizumab
10.3.1.5. Others
10.3.2. Chemotherapy
10.3.2.1. Mitomycin C
10.3.2.2. Docetaxel
10.3.2.3. Paclitaxel
10.3.2.4. Cisplatin
10.3.2.5. Others
10.3.3. Targeted therapy
10.3.3.1. Erdafitinib
10.3.3.2. Enfortumab vedotin-ejfv
10.3.3.3. Sacituzumab govitecan
10.3.3.4. Others
10.4. Market Attractiveness Analysis by Drug Type
11. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2019-2023
11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
11.3.1. Hospital Pharmacy
11.3.2. Retail Pharmacy
11.3.3. Specialty Pharmacy
11.3.4. Online Pharmacy
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2019-2023 and Forecast 2024-2033, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
12.3. Current Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy 2024-2033
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Bladder Cancer Type
13.3.3. By Cancer Grade
13.3.4. By Drug Type
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Bladder Cancer Type
13.4.3. By Cancer Grade
13.4.4. By Drug Type
13.4.5. By Distribution Channel
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis
13.7. Country-Level Analysis & Forecast
13.7.1. U.S. Market Analysis
13.7.1.1. .Introduction
13.7.1.2. Market Analysis and Forecast by Market Taxonomy
13.7.1.2.1. By Bladder Cancer Type
13.7.1.2.2. By Cancer Grade
13.7.1.2.3. By Drug Type
13.7.1.2.4. By Distribution Channel
13.7.2. Canada Market Analysis
13.7.2.1. Introduction
13.7.2.2. Market Analysis and Forecast by Market Taxonomy
13.7.2.2.1. By Bladder Cancer Type
13.7.2.2.2. By Cancer Grade
13.7.2.2.3. By Drug Type
13.7.2.2.4. By Distribution Channel
14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033
14.1. Introduction
14.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
14.3.1. By Country
14.3.1.1. Mexico
14.3.1.2. Brazil
14.3.1.3. Argentina
14.3.1.4. Rest of Latin America
14.3.2. By Bladder Cancer Type
14.3.3. By Cancer Grade
14.3.4. By Drug Type
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Bladder Cancer Type
14.4.3. By Cancer Grade
14.4.4. By Drug Type
14.4.5. By Distribution Channel
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis
14.7. Country-Level Analysis & Forecast
14.7.1. Mexico Market Analysis
14.7.1.1. Introduction
14.7.1.2. Market Analysis and Forecast by Market Taxonomy
14.7.1.2.1. By Bladder Cancer Type
14.7.1.2.2. By Cancer Grade
14.7.1.2.3. By Drug Type
14.7.1.2.4. By Distribution Channel
14.7.2. Brazil Market Analysis
14.7.2.1. Introduction
14.7.2.2. Market Analysis and Forecast by Market Taxonomy
14.7.2.2.1. By Bladder Cancer Type
14.7.2.2.2. By Cancer Grade
14.7.2.2.3. By Drug Type
14.7.2.2.4. By Distribution Channel
14.7.3. Argentina Market Analysis
14.7.3.1. Introduction
14.7.3.2. Market Analysis and Forecast by Market Taxonomy
14.7.3.2.1. By Bladder Cancer Type
14.7.3.2.2. By Cancer Grade
14.7.3.2.3. By Drug Type
14.7.3.2.4. By Distribution Channel
15. Europe Market Analysis 2019-2023 and Forecast 2024-2033
15.1. Introduction
15.2. Historical Market Size (US$ Bn) Analysis, By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. Poland
15.3.1.7. Russia
15.3.1.8. Rest of Europe
15.3.2. By Bladder Cancer Type
15.3.3. By Cancer Grade
15.3.4. By Drug Type
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Bladder Cancer Type
15.4.3. By Cancer Grade
15.4.4. By Drug Type
15.4.5. By Distribution Channel
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis
15.7. Country-Level Analysis & Forecast
15.7.1. Germany Market Analysis
15.7.1.1. Introduction
15.7.1.2. Market Analysis and Forecast by Market Taxonomy
15.7.1.2.1. By Bladder Cancer Type
15.7.1.2.2. By Cancer Grade
15.7.1.2.3. By Drug Type
15.7.1.2.4. By Distribution Channel
15.7.2. Italy Market Analysis
15.7.2.1. Introduction
15.7.2.2. Market Analysis and Forecast by Market Taxonomy
15.7.2.2.1. By Bladder Cancer Type
15.7.2.2.2. By Cancer Grade
15.7.2.2.3. By Drug Type
15.7.2.2.4. By Distribution Channel
15.7.3. France Market Analysis
15.7.3.1. Introduction
15.7.3.2. Market Analysis and Forecast by Market Taxonomy
15.7.3.2.1. By Bladder Cancer Type
15.7.3.2.2. By Cancer Grade
15.7.3.2.3. By Drug Type
15.7.3.2.4. By Distribution Channel
15.7.4. U.K. Market Analysis
15.7.4.1. Introduction
15.7.4.2. Market Analysis and Forecast by Market Taxonomy
15.7.4.2.1. By Bladder Cancer Type
15.7.4.2.2. By Cancer Grade
15.7.4.2.3. By Drug Type
15.7.4.2.4. By Distribution Channel
15.7.5. Spain Market Analysis
15.7.5.1. Introduction
15.7.5.2. Market Analysis and Forecast by Market Taxonomy
15.7.5.2.1. By Bladder Cancer Type
15.7.5.2.2. By Cancer Grade
15.7.5.2.3. By Drug Type
15.7.5.2.4. By Distribution Channel
15.7.6. Poland Market Analysis
15.7.6.1. Introduction
15.7.6.2. Market Analysis and Forecast by Market Taxonomy
15.7.6.2.1. By Bladder Cancer Type
15.7.6.2.2. By Cancer Grade
15.7.6.2.3. By Drug Type
15.7.6.2.4. By Distribution Channel
15.7.7. Russia Market Analysis
15.7.7.1. Introduction
15.7.7.2. Market Analysis and Forecast by Market Taxonomy
15.7.7.2.1. By Bladder Cancer Type
15.7.7.2.2. By Cancer Grade
15.7.7.2.3. By Drug Type
15.7.7.2.4. By Distribution Channel
16. South Asia Market Analysis 2019-2023 and Forecast 2024-2033
16.1. Introduction
16.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Indonesia
16.3.1.3. Malaysia
16.3.1.4. Thailand
16.3.1.5. Rest of South Asia
16.3.2. By Bladder Cancer Type
16.3.3. By Cancer Grade
16.3.4. By Drug Type
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Bladder Cancer Type
16.4.3. By Cancer Grade
16.4.4. By Drug Type
16.4.5. By Distribution Channel
16.5. Key Market Participants - Intensity Mapping
16.6. Drivers and Restraints - Impact Analysis
16.7. Country-Level Analysis & Forecast
16.7.1. India Market Analysis
16.7.1.1. Introduction
16.7.1.2. Market Analysis and Forecast by Market Taxonomy
16.7.1.2.1. By Bladder Cancer Type
16.7.1.2.2. By Cancer Grade
16.7.1.2.3. By Drug Type
16.7.1.2.4. By Distribution Channel
16.7.2. Indonesia Market Analysis
16.7.2.1. Introduction
16.7.2.2. Market Analysis and Forecast by Market Taxonomy
16.7.2.2.1. By Bladder Cancer Type
16.7.2.2.2. By Cancer Grade
16.7.2.2.3. By Drug Type
16.7.2.2.4. By Distribution Channel
16.7.3. Malaysia Market Analysis
16.7.3.1. Introduction
16.7.3.2. Market Analysis and Forecast by Market Taxonomy
16.7.3.2.1. By Bladder Cancer Type
16.7.3.2.2. By Cancer Grade
16.7.3.2.3. By Drug Type
16.7.3.2.4. By Distribution Channel
16.7.4. Thailand Market Analysis
16.7.4.1. Introduction
16.7.4.2. Market Analysis and Forecast by Market Taxonomy
16.7.4.2.1. By Bladder Cancer Type
16.7.4.2.2. By Cancer Grade
16.7.4.2.3. By Drug Type
16.7.4.2.4. By Distribution Channel
17. East Asia Market Analysis 2019-2023 and Forecast 2024-2033
17.1. Introduction
17.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Bladder Cancer Type
17.3.3. By Cancer Grade
17.3.4. By Drug Type
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Bladder Cancer Type
17.4.3. By Cancer Grade
17.4.4. By Drug Type
17.4.5. By Distribution Channel
17.5. Key Market Participants - Intensity Mapping
17.6. Drivers and Restraints - Impact Analysis
17.7. Country-Level Analysis & Forecast
17.7.1. China Market Analysis
17.7.1.1. Introduction
17.7.1.2. Market Analysis and Forecast by Market Taxonomy
17.7.1.2.1. By Bladder Cancer Type
17.7.1.2.2. By Cancer Grade
17.7.1.2.3. By Drug Type
17.7.1.2.4. By Distribution Channel
17.7.2. Japan Market Analysis
17.7.2.1. Introduction
17.7.2.2. Market Analysis and Forecast by Market Taxonomy
17.7.2.2.1. By Bladder Cancer Type
17.7.2.2.2. By Cancer Grade
17.7.2.2.3. By Drug Type
17.7.2.2.4. By Distribution Channel
17.7.3. South Korea Drugs Market Analysis
17.7.3.1. Introduction
17.7.3.2. Market Analysis and Forecast by Market Taxonomy
17.7.3.2.1. By Bladder Cancer Type
17.7.3.2.2. By Cancer Grade
17.7.3.2.3. By Drug Type
17.7.3.2.4. By Distribution Channel
18. Oceania Market 2019-2023 and Forecast 2024-2033
18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Bladder Cancer Type
18.3.3. By Cancer Grade
18.3.4. By Drug Type
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Bladder Cancer Type
18.4.3. By Cancer Grade
18.4.4. By Drug Type
18.4.5. By Distribution Channel
18.5. Key Market Participants - Intensity Mapping
18.6. Drivers and Restraints - Impact Analysis
18.7. Country-Level Analysis & Forecast
18.7.1. Australia Market Analysis
18.7.1.1. Introduction
18.7.1.2. Market Analysis and Forecast by Market Taxonomy
18.7.1.2.1. By Bladder Cancer Type
18.7.1.2.2. By Cancer Grade
18.7.1.2.3. By Drug Type
18.7.1.2.4. By Distribution Channel
18.7.2. New Zealand Market Analysis
18.7.2.1. Introduction
18.7.2.2. Market Analysis and Forecast by Market Taxonomy
18.7.2.2.1. By Bladder Cancer Type
18.7.2.2.2. By Cancer Grade
18.7.2.2.3. By Drug Type
18.7.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033
19.1. Introduction
19.2. Historical Market Size (US$ Bn) and Trend Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Bn) Analysis, By Market Taxonomy, 2024-2033
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. South Africa
19.3.1.3. North Africa
19.3.1.4. Türkiye
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Bladder Cancer Type
19.3.3. By Cancer Grade
19.3.4. By Drug Type
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Bladder Cancer Type
19.4.3. By Cancer Grade
19.4.4. By Drug Type
19.4.5. By Distribution Channel
19.5. Key Market Participants - Intensity Mapping
19.6. Drivers and Restraints - Impact Analysis
19.7. Country-Level Analysis & Forecast
19.7.1. GCC Countries Market Analysis
19.7.1.1. Introduction
19.7.1.2. Market Analysis and Forecast by Market Taxonomy
19.7.1.2.1. By Bladder Cancer Type
19.7.1.2.2. By Cancer Grade
19.7.1.2.3. By Drug Type
19.7.1.2.4. By Distribution Channel
19.7.2. South Africa Market Analysis
19.7.2.1. Introduction
19.7.2.2. Market Analysis and Forecast by Market Taxonomy
19.7.2.2.1. By Bladder Cancer Type
19.7.2.2.2. By Cancer Grade
19.7.2.2.3. By Drug Type
19.7.2.2.4. By Distribution Channel
19.7.3. North Africa Market Analysis
19.7.3.1. Introduction
19.7.3.2. Market Analysis and Forecast by Market Taxonomy
19.7.3.2.1. By Bladder Cancer Type
19.7.3.2.2. By Cancer Grade
19.7.3.2.3. By Drug Type
19.7.3.2.4. By Distribution Channel
19.7.4. Türkiye Market Analysis
19.7.4.1. Introduction
19.7.4.2. Market Analysis and Forecast by Market Taxonomy
19.7.4.2.1. By Bladder Cancer Type
19.7.4.2.2. By Cancer Grade
19.7.4.2.3. By Drug Type
19.7.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
20.3.1. By Regional footprint of Players
20.3.2. Product footprint by Players
20.3.3. Channel Foot Print by Players
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive [Tentative list]
21.3.1. Pfizer Inc.
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Business Segment Overview
21.3.1.4. Sales Footprint
21.3.1.5. SWOT Analysis
21.3.1.6. Key Financials
21.3.1.7. Strategy Overview
21.3.2. Merck KGaA
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Business Segment Overview
21.3.2.4. Sales Footprint
21.3.2.5. SWOT Analysis
21.3.2.6. Key Financials
21.3.2.7. Strategy Overview
21.3.3. Merck & Co
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Business Segment Overview
21.3.3.4. Sales Footprint
21.3.3.5. SWOT Analysis
21.3.3.6. Key Financials
21.3.3.7. Strategy Overview
21.3.4. AstraZeneca PLC
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Business Segment Overview
21.3.4.4. Sales Footprint
21.3.4.5. SWOT Analysis
21.3.4.6. Key Financials
21.3.4.7. Strategy Overview
21.3.5. Roche Holding AG (Genentech)
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Business Segment Overview
21.3.5.4. Sales Footprint
21.3.5.5. SWOT Analysis
21.3.5.6. Key Financials
21.3.5.7. Strategy Overview
21.3.6. Astellas Pharma Inc.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Business Segment Overview
21.3.6.4. Sales Footprint
21.3.6.5. SWOT Analysis
21.3.6.6. Key Financials
21.3.6.7. Strategy Overview
21.3.7. J&J (Janssen Biotech)
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Business Segment Overview
21.3.7.4. Sales Footprint
21.3.7.5. SWOT Analysis
21.3.7.6. Key Financials
21.3.7.7. Strategy Overview
21.3.8. Cipla Inc.
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Business Segment Overview
21.3.8.4. Sales Footprint
21.3.8.5. SWOT Analysis
21.3.8.6. Key Financials
21.3.8.7. Strategy Overview
21.3.9. Amneal Pharma
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Business Segment Overview
21.3.9.4. Sales Footprint
21.3.9.5. SWOT Analysis
21.3.9.6. Key Financials
21.3.9.7. Strategy Overview
21.3.10. Bristol Myers Squibb Co.
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Business Segment Overview
21.3.10.4. Sales Footprint
21.3.10.5. SWOT Analysis
21.3.10.6. Key Financials
21.3.10.7. Strategy Overview
21.3.11. Dr. Reddy’s Laboratories, Inc.
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Business Segment Overview
21.3.11.4. Sales Footprint
21.3.11.5. SWOT Analysis
21.3.11.6. Key Financials
21.3.11.7. Strategy Overview
21.3.12. Gilead Sciences Inc.
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Business Segment Overview
21.3.12.4. Sales Footprint
21.3.12.5. SWOT Analysis
21.3.12.6. Key Financials
21.3.12.7. Strategy Overview
21.3.13. Endo Pharma
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Business Segment Overview
21.3.13.4. Sales Footprint
21.3.13.5. SWOT Analysis
21.3.13.6. Key Financials
21.3.13.7. Strategy Overview
21.3.14. UroGen Pharma, Inc.
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Business Segment Overview
21.3.14.4. Sales Footprint
21.3.14.5. SWOT Analysis
21.3.14.6. Key Financials
21.3.14.7. Strategy Overview
21.3.15. Teva Pharmaceuticals (Actavis)
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. Business Segment Overview
21.3.15.4. Sales Footprint
21.3.15.5. SWOT Analysis
21.3.15.6. Key Financials
21.3.15.7. Strategy Overview
21.3.16. Hikma Pharmaceuticals
21.3.16.1. Overview
21.3.16.2. Product Portfolio
21.3.16.3. Business Segment Overview
21.3.16.4. Sales Footprint
21.3.16.5. SWOT Analysis
21.3.16.6. Key Financials
21.3.16.7. Strategy Overview
21.3.17. Incyte
21.3.17.1. Overview
21.3.17.2. Product Portfolio
21.3.17.3. Business Segment Overview
21.3.17.4. Sales Footprint
21.3.17.5. SWOT Analysis
21.3.17.6. Key Financials
21.3.17.7. Strategy Overview

22. Assumptions and Acronyms Used

23. Research Methodology